Highlighting Fibroblasts Activation in Fibrosis: The State-of-The-Art Fibroblast Activation Protein Inhibitor PET Imaging in Cardiovascular Diseases
暂无分享,去创建一个
[1] T. Derlin,et al. Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors , 2023, European Journal of Nuclear Medicine and Molecular Imaging.
[2] Q. Lin,et al. Extranodal Rosai-Dorfman disease involving pulmonary artery detected by ^68Ga-FAPI PET/CT and fused ^68Ga-FAPI PET/MRI , 2023, European Journal of Nuclear Medicine and Molecular Imaging.
[3] M. Uder,et al. Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT , 2022, European Journal of Nuclear Medicine and Molecular Imaging.
[4] Jun Zhao,et al. Non-tumoral uptake of 68Ga-FAPI-04 PET: A retrospective study , 2022, Frontiers in Oncology.
[5] Kuangyu Shi,et al. [68Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling , 2022, European Journal of Nuclear Medicine and Molecular Imaging.
[6] Xiao Zhang,et al. Different displays of ^13N-NH_3 myocardial perfusion and cardiac ^68Ga-FAPI PET in immune checkpoint inhibitor–associated myocarditis-induced heart failure , 2022, European Journal of Nuclear Medicine and Molecular Imaging.
[7] S. Dorbala. Fibroblast Activation: A Novel Mechanism of Heart Failure in Light Chain Cardiac Amyloidosis? , 2022, JACC. Cardiovascular imaging.
[8] Xiao Zhang,et al. ^68Ga-FAPI PET visualize heart failure: from mechanism to clinic , 2022, European Journal of Nuclear Medicine and Molecular Imaging.
[9] Y. Zhang,et al. Myocardial Activity at 18F-FAPI PET/CT and Risk for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. , 2022, Radiology.
[10] Yan-hui Sheng,et al. Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy , 2022, Frontiers in Pharmacology.
[11] Gui-xia Pan,et al. Molecular imaging of fibroblast activity in pressure overload heart failure using [^68 Ga]Ga-FAPI-04 PET/CT , 2022, European Journal of Nuclear Medicine and Molecular Imaging.
[12] D. Mandry,et al. Detection of acute myocarditis by ECG-triggered PET imaging of somatostatin receptors compared to cardiac magnetic resonance: preliminary results , 2022, Journal of Nuclear Cardiology.
[13] X. Qin,et al. Early detection of radiation-induced myocardial damage by [^18F]AlF-NOTA-FAPI-04 PET/CT imaging , 2022, European Journal of Nuclear Medicine and Molecular Imaging.
[14] Shuyang Zhang,et al. Feasibility of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Light-Chain Cardiac Amyloidosis. , 2022, JACC. Cardiovascular imaging.
[15] Wei Han,et al. A clinical study on relationship between visualization of cardiac fibroblast activation protein activity by Al18F-NOTA-FAPI-04 positron emission tomography and cardiovascular disease , 2022, Frontiers in Cardiovascular Medicine.
[16] C. Qin,et al. Noninvasive Monitoring of Reparative Fibrosis after Myocardial Infarction in Rats Using 68Ga-FAPI-04 PET/CT. , 2022, Molecular pharmaceutics.
[17] Yuanhua Yang,et al. Pulmonary artery imaging with 68 Ga-FAPI-04 in patients with chronic thromboembolic pulmonary hypertension , 2022, Journal of Nuclear Cardiology.
[18] Y. Liu,et al. Case Report: Multimodal Imaging Guides the Management of an Eosinophilic Leukemia Patient With Eosinophilic Myocarditis and Intracardiac Thrombus , 2022, Frontiers in Cardiovascular Medicine.
[19] H. Kauczor,et al. Repetitive Early 68Ga-FAPI PET Acquisition Comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions , 2022, The Journal of Nuclear Medicine.
[20] J. Björkegren,et al. Atherosclerosis: Recent developments , 2022, Cell.
[21] Jian Zhang,et al. DP1 (Prostaglandin D2 Receptor 1) Activation Protects Against Vascular Remodeling and Vascular Smooth Muscle Cell Transition to Myofibroblasts in Angiotensin II–Induced Hypertension in Mice , 2022, Hypertension.
[22] Zuoquan Zhao,et al. ^68Ga-FAPI PET/CT for molecular assessment of fibroblast activation in right heart in pulmonary arterial hypertension: a single-center, pilot study , 2022, Journal of Nuclear Cardiology.
[23] Jinming Yu,et al. [18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers , 2022, European Journal of Nuclear Medicine and Molecular Imaging.
[24] K. Imanaka-Yoshida,et al. The Pathogenesis of Cardiac Fibrosis: A Review of Recent Progress , 2022, International journal of molecular sciences.
[25] T. Derlin,et al. Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome , 2022, The Journal of Nuclear Medicine.
[26] X. Yang,et al. Increased 68Ga-FAPI Uptake in Active Atherosclerotic Plaque. , 2022, Clinical Nuclear Medicine.
[27] M. Henein,et al. Detection of myocardial fibrosis by speckle-tracking echocardiography: from prediction to clinical applications , 2022, Heart Failure Reviews.
[28] L. Huo,et al. Increased 68Ga-FAPI Uptake of Symptomatic Intracranial Atherosclerotic Plaque Revealed by PET/MR. , 2022, Clinical nuclear medicine.
[29] D. Weissman,et al. CAR T cells produced in vivo to treat cardiac injury , 2022, Science.
[30] J. McMurray,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2022, European journal of heart failure.
[31] Haojun Chen,et al. 68Ga FAPI PET/MRI in Cardiac Amyloidosis. , 2021, Radiology.
[32] Hubing Wu,et al. [18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04 , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[33] Z. Fayad,et al. Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation , 2021, Scientific Reports.
[34] S. Nekolla,et al. Visualization of thermal damage using 68 Ga-FAPI-PET/CT after pulmonary vein isolation , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[35] J. Czernin,et al. Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study , 2021, The Journal of Nuclear Medicine.
[36] Sinem Nihal Esatoglu,et al. Takayasu arteritis. , 2021, Current opinion in rheumatology.
[37] Shihua Zhao,et al. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[38] Shuyang Zhang,et al. Immune checkpoint inhibitor-associated cardiotoxicity detected by 68Ga-DOTATATE PET/CT and 68Ga-FAPI PET/CT. , 2021, European heart journal. Cardiovascular Imaging.
[39] M. Hacker,et al. Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls , 2021, The Journal of Nuclear Medicine.
[40] R. Bonow,et al. Myocardial Viability Assessment Before Surgical Revascularization in Ischemic Cardiomyopathy: JACC Review Topic of the Week. , 2021, Journal of the American College of Cardiology.
[41] Xiaotang Yang,et al. Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review , 2021, Frontiers in Oncology.
[42] Xue-juan Wang,et al. 68Ga-FAPI PET/MRI in Coronary Heart Disease , 2021, Journal of Nuclear Cardiology.
[43] Shaobo Yao,et al. Cerebral Venous Sinus Thrombosis Caused by Neuro-Behçet Disease Accidentally Detected by 68Ga-FAPI PET/CT. , 2021, Clinical nuclear medicine.
[44] J. Debus,et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[45] Jacob C. Ulirsch,et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants , 2021, Nature Genetics.
[46] L. Umutlu,et al. Visualization of Fibroblast Activation After Myocardial Infarction Using 68Ga-FAPI PET , 2021, Clinical nuclear medicine.
[47] Shaobo Yao,et al. Diffuse uptake of [68Ga]Ga-FAPI in the left heart in a patient with hypertensive heart disease by PET/CT , 2021, Journal of Nuclear Cardiology.
[48] Liang Zhao,et al. 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for the Evaluation of Disease Activity in Takayasu Arteritis. , 2021, Clinical nuclear medicine.
[49] S. Nekolla,et al. Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04 , 2021, Journal of Nuclear Cardiology.
[50] K. Cheng,et al. Cardiac fibrosis: myofibroblast-mediated pathological regulation and drug delivery strategies. , 2021, Advanced drug delivery reviews.
[51] U. Haberkorn,et al. Early Detection of Checkpoint Inhibitor-Associated Myocarditis Using 68Ga-FAPI PET/CT , 2021, Frontiers in Cardiovascular Medicine.
[52] K. Kerr,et al. Chronic Thromboembolic Pulmonary Hypertension: JACC Focus Seminar. , 2020, Journal of the American College of Cardiology.
[53] Nikolaos G. Frangogiannis,et al. Cardiac fibrosis. , 2020, Cardiovascular research.
[54] Zuoquan Zhao,et al. 68Ga-FAPI right heart uptake in a patient with idiopathic pulmonary arterial hypertension , 2020, Journal of Nuclear Cardiology.
[55] Ya-wen Wang,et al. 68Ga-FAPI-04 Accumulation in Myocardial Infarction in a Patient With Neuroendocrine Carcinoma. , 2020, Clinical nuclear medicine.
[56] S. Nekolla,et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling , 2020, Journal of Nuclear Cardiology.
[57] U. Reineke,et al. 571P Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP) , 2020 .
[58] U. Haberkorn,et al. Relationship Between Cardiac Fibroblast Activation Protein Activity by Positron Emission Tomography and Cardiovascular Disease , 2020, Circulation. Cardiovascular imaging.
[59] J. Elrod,et al. Myofibroblasts and Fibrosis , 2020, Circulation research.
[60] F. Ruschitzka,et al. Deletion of fibroblast activation protein provides atheroprotection. , 2020, Cardiovascular research.
[61] Torsten Kuwert,et al. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor , 2020, The Journal of Nuclear Medicine.
[62] A. Tefferi,et al. WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic , 2020, American journal of hematology.
[63] M. Dweck,et al. Myocardial fibrosis: why image, how to image and clinical implications , 2019, Heart.
[64] M. Totzeck,et al. Cardiac fibroblast activation detected by positron emission tomography/computed tomography as a possible sign of cardiotoxicity. , 2019, European heart journal.
[65] T. Watabe,et al. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models , 2019, The Journal of Nuclear Medicine.
[66] Thomas Lindner,et al. Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention , 2019, The Journal of Nuclear Medicine.
[67] E. Jones,et al. 68Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. , 2019, Radiology. Imaging cancer.
[68] J. Moon,et al. Myocardial Amyloidosis: The Exemplar Interstitial Disease. , 2019, JACC. Cardiovascular imaging.
[69] J. Epstein,et al. Targeting Cardiac Fibrosis with Engineered T cells , 2019, Nature.
[70] J. Moon,et al. Multimodality Imaging Markers of Adverse Myocardial Remodeling in Aortic Stenosis. , 2019, JACC. Cardiovascular imaging.
[71] N. Frangogiannis,et al. Fibroblasts in the Infarcted, Remodeling, and Failing Heart , 2019, JACC. Basic to translational science.
[72] H. Roderick,et al. Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure. , 2019, Journal of the American College of Cardiology.
[73] Z. Fayad,et al. 68Ga-DOTATATE PET Identifies Residual Myocardial Inflammation and Bone Marrow Activation After Myocardial Infarction , 2019, Journal of the American College of Cardiology.
[74] H. Kauczor,et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.
[75] Stephan G. Nekolla,et al. Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04 , 2019, The Journal of Nuclear Medicine.
[76] E. Tombetti,et al. Takayasu arteritis: advanced understanding is leading to new horizons , 2019, Rheumatology.
[77] Haniye Sadat Sajadi,et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.
[78] Thomas Lindner,et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.
[79] Frederik L. Giesel,et al. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers , 2018, The Journal of Nuclear Medicine.
[80] E. V. van Beek,et al. Progression of Hypertrophy and Myocardial Fibrosis in Aortic Stenosis , 2018, Circulation. Cardiovascular imaging.
[81] J. Butler,et al. Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. , 2018, Journal of the American College of Cardiology.
[82] J. Molkentin,et al. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart , 2018, The Journal of clinical investigation.
[83] E. Puré,et al. Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts. , 2017, Matrix biology : journal of the International Society for Matrix Biology.
[84] M. Lindsey,et al. Cardiac Fibroblast Activation Post-Myocardial Infarction: Current Knowledge Gaps. , 2017, Trends in pharmacological sciences.
[85] T. Münzel,et al. From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension , 2017, Thrombosis and Haemostasis.
[86] S. Lensing,et al. Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis. , 2016, JACC. Cardiovascular imaging.
[87] Malina J. Ivey,et al. Defining the Cardiac Fibroblast. , 2016, Circulation journal : official journal of the Japanese Circulation Society.
[88] S. Prabhu,et al. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. , 2016, Circulation research.
[89] K. Yutzey,et al. Cardiac Fibrosis: The Fibroblast Awakens. , 2016, Circulation research.
[90] D. Sutherlin,et al. Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21* , 2016, The Journal of Biological Chemistry.
[91] H. Kaufman,et al. Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis , 2015, Nature Reviews Drug Discovery.
[92] P. Galuppo,et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. , 2015, Journal of molecular and cellular cardiology.
[93] H. Sillesen,et al. 64Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[94] E. McNally,et al. The genetic landscape of cardiomyopathy and its role in heart failure. , 2015, Cell metabolism.
[95] Z. Rancic,et al. Evaluation of the Radiolabeled Boronic Acid-Based FAP Inhibitor MIP-1232 for Atherosclerotic Plaque Imaging , 2015, Molecules.
[96] O. Schilling,et al. Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy , 2014, Proteomics. Clinical applications.
[97] S. Conway,et al. Origin, development, and differentiation of cardiac fibroblasts. , 2014, Journal of molecular and cellular cardiology.
[98] A. Lambeir,et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). , 2014, Journal of medicinal chemistry.
[99] N. Frangogiannis,et al. The pathogenesis of cardiac fibrosis , 2013, Cellular and Molecular Life Sciences.
[100] W. Fang,et al. Comparison of 99mTc-MIBI SPECT/18F-FDG PET Imaging and Cardiac Magnetic Resonance Imaging in Patients With Idiopathic Dilated Cardiomyopathy: Assessment of Cardiac Function and Myocardial Injury , 2012, Clinical nuclear medicine.
[101] M. Ackerman,et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. , 2011, Journal of the American College of Cardiology.
[102] Pierre Croisille,et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. , 2011, Journal of the American College of Cardiology.
[103] S. Hoerstrup,et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata , 2011, European heart journal.
[104] E. Domenichini,et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[105] Stephanie L. K. Bowers,et al. The extracellular matrix: at the center of it all. , 2010, Journal of molecular and cellular cardiology.
[106] M. Reiser,et al. In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors , 2010, Journal of Nuclear Medicine.
[107] Giulio Gabbiani,et al. The myofibroblast: one function, multiple origins. , 2007, The American journal of pathology.
[108] P. McKee,et al. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. , 2007, Archives of biochemistry and biophysics.
[109] A. Ignaszewski,et al. Eosinophilic myocarditis: case series and review of literature. , 2006, The Canadian journal of cardiology.
[110] N. Frangogiannis. Chemokines in the ischemic myocardium: from inflammation to fibrosis , 2004, Inflammation Research.
[111] P. McKee,et al. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. , 2004, Blood.
[112] S. Larson,et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[113] C. Abbott,et al. Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis , 1999, Hepatology.
[114] G. Mengod,et al. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5expression in human pituitary, gastroentero‐pancreatic and mammary tumors , 1997 .
[115] A. Scott,et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] S S Gambhir,et al. Quantification of Regional Myocardial Blood Flow Using 13N‐Ammonia and Reoriented Dynamic Positron Emission Tomographic Imaging , 1992, Circulation.
[117] D E Kuhl,et al. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. , 1990, Journal of the American College of Cardiology.
[118] D. Kuhl,et al. N‐13 Ammonia as an Indicator of Myocardial Blood Flow , 1981, Circulation.
[119] P. Ogbogu,et al. Hypereosinophilic Syndrome , 2015, Clinical reviews in allergy and immunology.
[120] H. Sillesen,et al. Cu-DOTATATE PET / MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques Studies in Patients Undergoing Endarterectomy , 2015 .
[121] W. Roberts,et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. , 2000, Journal of the American College of Cardiology.